Voyager Therapeutics (VYGR) Free Cash Flow (2014 - 2026)
Voyager Therapeutics (VYGR) posted Free Cash Flow of -$33.4 million for Q1 2026, down 16.41% sequentially from -$28.7 million in Q4 2025, and up 13.28% YoY from -$29.5 million in Q1 2025.
Voyager Therapeutics (VYGR) Free Cash Flow (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Free Cash Flow for 13 years, with the latest figure at -$33.4 million in Q1 2026.
- Quarterly Free Cash Flow rose 13.28% year-over-year to -$33.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$127.8 million (down 10.02% YoY) and the FY2025 annual result came in at -$132.9 million, down 605.72% from the prior year.
- Free Cash Flow retreated to -$33.4 million in Q1 2026 per VYGR's latest filing, from -$28.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $123.1 million in Q1 2023 and troughed at -$38.6 million in Q1 2025.
- A 5-year average of -$7.4 million and a median of -$23.5 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow jumped 259.83% in 2023, then sank 9072.75% in 2024.
- Over 5 years, Free Cash Flow stood at -$13.2 million in 2022, then slumped by 86.04% to -$24.5 million in 2023, then soared by 40.1% to -$14.7 million in 2024, then plunged by 95.59% to -$28.7 million in 2025, then declined by 16.41% to -$33.4 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$33.4 million, -$28.7 million, and -$31.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Voyager Therapeutics | 205.86 Mn | 89.52 Mn | - | -26.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.04 Mn |
| Jun 30, 2026 | -26.04 Mn |
| Mar 31, 2026 | -33.43 Mn |
| Mar 31, 2026 | -33.43 Mn |
| Dec 31, 2025 | -28.72 Mn |
| Dec 31, 2025 | -28.72 Mn |
| Sep 30, 2025 | -31.26 Mn |
| Sep 30, 2025 | -31.26 Mn |
| Jun 30, 2025 | -34.37 Mn |
| Jun 30, 2025 | -34.37 Mn |
| Mar 31, 2025 | -38.55 Mn |
| Mar 31, 2025 | -38.55 Mn |
| Dec 31, 2024 | -14.68 Mn |
| Dec 31, 2024 | -14.68 Mn |
| Sep 30, 2024 | -28.23 Mn |
| Sep 30, 2024 | -28.23 Mn |
| Jun 30, 2024 | -34.67 Mn |
| Jun 30, 2024 | -34.67 Mn |
| Mar 31, 2024 | 58.75 Mn |
| Mar 31, 2024 | 58.75 Mn |